Denmark-based Forward Pharma A/S today announced it has commenced an underwritten initial public offering (IPO) of its American Depositary Shares (ADSs).
Forward is a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis.
The company currently expects the IPO price to be between $20.00 and $22.00 and the ADSs are expected to trade on the Nasdaq under the ticker symbol "FWP." Leerink Partners LLC, Jefferies and RBC Capital Markets are acting as book-running managers. JMP Securities is acting as co-manager.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze